Autopsy report · NCT00737763

Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab

“drug withdrawn from market”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Emory University

Sponsor type

University, hospital or other

Conditions

Diabetes Mellitus, Type 1

Interventions

efalizumab; placebo

Participants

0

Trials that died the same way

• The Sub-Sero Study
  “Drug supply withdrawn (dec 2019)” (82% match in meaning)
• Lapatinib and Bortezomib in Patients With Advanced Malignancies
  “Drug support withdrawn” (73% match in meaning)
• Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
  “Withdrawal of drug supply/funding” (72% match in meaning)
• Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
  “Withdrawn due to toxicity” (70% match in meaning)
• 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
  “Pharmaceutical Company withdrew support and investigational product” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.